ClinicalTrials.gg
CompletedNCT03580109THERMOEDEMEUpdated Nov 6, 2026

Spa Therapy for Upper or Lower Limb Lymphoedema

An interventional study of Immediate spa treatment and Late spa treatment in Lymphoedema, Breast Cancer and Malignant Disease, sponsored by Association Francaise pour la Recherche Thermale. Completed at 13 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Association Francaise pour la Recherche Thermale · Not applicable, Interventional, and Other

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Lymphedema with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Lymphedema · France.

Enrollment
Largest of 18
160 · median 53
Started
2019
with 1 other
No phase
17 of 29
5 open now
Registered
13th of 29
by date
Lead sponsor
1 of 29
Association Francaise pour la Recherche Thermale

Among the 29 studies in Lymphedema with a site in France, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is one of 17 with no phase, and was the 13th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

6 of the 29 studies in Lymphedema with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lymphedema with a site in France, or all of them as a file.
02

Study summary

THERMOEDEME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial.

The aim of this study is to evaluate effects of spa therapy in phlebology with a therapeutic education program in daily life of patients suffering lymphoedema.

Read the detailed description

Lymphoedema is a chronic disease related to an insufficiency of the lymphatic system, which most often affects the limbs. Secondary forms are the most common, particularly those following surgical and radiotherapy treatments for cancer, the most classic being the post-therapeutic large arm of breast cancer.

The lymphoedema is a traditional phlebology indication in spa therapy. The spa therapy linked with therapeutic education could constitute a favorable environment for the treatment of lymphoedema.

The primary endpoint is the comparison of the rate of patients improved from baseline to 6 months on LMS27 (upper limb lymphoedema) or LYMQOL-LEG (lower limb lymphoedema) (Improvement is defined as 7 points between baseline and 6-month follow-up).

03

Conditions studied

  • Lymphoedema
  • Breast Cancer
  • Malignant Disease
  • Gynaecological Cancer
  • Lymphoma
  • Prostate Cancer

Keywords

  • Lymphoedema
  • Post breast cancer
  • Spa therapy
  • Education therapeutic
  • Malignant Disease
  • Post gynaecological cancer
  • Post Lymphoma
  • Post prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old and older
  • available for a spa treatment (phlebology indication) during 18 days and a follow up period of 15 months
  • with permanent lymphoedema of the upper or lower limb (2 ou 3 stade of International Society for Lymphology scale)
  • voluntary to participate to the study, form signed after appropriate information
  • affiliation to the social security system or equivalent

Exclusion criteria

Exclusion Criteria:

  • cancer undergoing chemotherapy and radiotherapy treatment in primary phase
  • the baseline score of LMS27 or LYMQOL-LEG > 79
  • pain of upper limb linked with a radical plexitis
  • of spa treatment (cancer in progress, psychiatrics disorders, immunodeficiency)
  • Erysipelas case history in the last 6 months or pachyderma and lymphangiectasia
  • no previous spa treatment for upper limb lymphoedema during the spa year
  • risk of intensive treatment in the next 6 months
  • subject participating to an other clinical study interventional
  • pregnancy, parturient or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Immediate spa treatment

    Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts

    Other: Immediate spa treatment

  • Sham comparator
    Late spa treatment

    Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization

    Other: Late spa treatment

Interventions

  • OtherImmediate spa treatment

    Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)

  • OtherLate spa treatment

    Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)

06

What researchers measure

Primary outcomes

  1. Evolution of lymphoedema quality of life assessed by the rate of patient with an improvement of the LMS27 scale (for upper limb lymphoedema).

    Rate of patients with an improvement of 7 points minimum of the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 months. The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (worse outcome) to 5 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 months

  2. Evolution of lymphoedema quality of life assessed by the rate of patient with an improvement of the LYMQOL-LEG scale (for lower limb lymphoedema).

    Rate of patients with an improvement of 7 points minimum of the LYMQOL-LEG scale (specific quality of life scale in lower limb lymphoedema) at 6 months. The LYMQOL-LEG scale is composed of 26 questions with 4 answers possible: not at all, a little, quite a bit, a lot. In order to to standardize with the LMS27 scale (for upper limb lymphoedema), the quotations are reversed: the answer's score is respectively 1 (worse outcome) to 4 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 months

Secondary outcomes

  1. Evolution of lymphoedema quality of life assessed by the LMS27 scale (for upper limb lymphoedema) before / after spa therapy.

    Evolution of the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 and 12 months. The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (worse outcome) to 5 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 and 12 months

  2. Evolution of lymphoedema quality of life assessed by the LYMQOL-LEG scale (for lower limb lymphoedema) before / after spa therapy.

    Evolution of the LYMQOL-LEG scale (specific quality of life scale in lower limb lymphoedema) at 6 and 12 months. The LYMQOL-LEG scale is composed of 26 questions with 4 answers possible: not at all, a little, quite a bit, a lot. In order to to standardize with the LMS27 scale (for upper limb lymphoedema), the quotations are reversed: the answer's score is respectively 1 (worse outcome) to 4 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 and 12 months

  3. Evolution of lymphoedema quality of life assessed by the most embarrassing items of the LMS27 scale (for upper lymphoedema).

    Evolution of 5 items the most embarrassing chosen by the patients in the LMS27 scale (specific quality of life scale in upper limb lymphoedema) at 6 and 12 months. The LMS27 scale is composed of 27 questions with 5 answers possible : never, rarely, sometimes, often, always. The answer's score is respectively 1 (worse outcome) to 5 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 and 12 months

  4. Evolution of lymphoedema quality of life assessed by the most embarrassing items of the LYMQOL-LEG scale (for lower limb lymphoedema)

    Evolution of 5 items the most embarrassing chosen by the patients in the LYMQOL-LEG scale (specific quality of life scale in lower limb lymphoedema) at 6 and 12 months. The LYMQOL-LEG scale is composed of 26 questions with 4 answers possible: not at all, a little, quite a bit, a lot. In order to to standardize with the LMS27 scale (for upper limb lymphoedema), we decide to reverse the quotations: the answer's score is respectively 1 (worse outcome) to 4 (better outcome). The higher the score is, the better the lymphoedema quality of life is.

    Time frame: 6 and 12 months

  5. Improvement of quality of life assessed by the generic quality of life: Euroquol EQ5D-3L

    Improvement of generic quality of life (the Euroquol EQ5D-3L scale) at 6 and 12 months. EQ5D-3L is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of lige that can be used in a wide range of health conditions and treatments. The EQ5D-3L has 6 items intended to measure general health. The top 5 rate mobility, independence, daily activities, pain / discomfort, and anxiety / depression, and are rated according to 3 values from "No problem" to "Problem" or "Incapacity". This results in an index score. The last item deals with perceived health on the day the questionnaire is filled in and uses a visual analogue scale from 0 (wors) to 100 (best health possible) (Visual Analog Scale Score)

    Time frame: 6 and 12 months

  6. Upper or lower limb evaluation

    Evolution of the volume of the upper or lower extremity evaluated (overall and then by segment) from staged perimeter measurements at 6 and 12 months.

    Time frame: 6 and 12 months

  7. Consumption of care between the 2 groups (immediate treatment/delayed treatment)

    Evaluation of the costs incurred by lymphoedema (hospitalisations, medical and paramedical acts, treatments).

    Time frame: 6 and 12 months

  8. Compliance of spa therapy

    Evaluation of the spa therapy compliance : number of health care performed in spa therapy.

    Time frame: After spa therapy

  9. Achievement educational aims

    Verification of the achievement of educational targets in spa therapy by phone follow up.

    Time frame: 3 months, 9 months.

  10. Adverse events

    Evaluation of all adverse events related to treatment, or not, according to the usual criteria of pharmacovigilance in clinical trials.

    Time frame: 12 months

  11. Functional evaluation

    Monthly measurements of functional discomfort from inclusion to 12 months; The functional discomfort is measured monthly by a visual scale : not discomfort to maximal discomfort.

    Time frame: 12 months

  12. Long term evaluation

    Evaluation of the maintenance of benefits at 12 months (stability of the long term effect) on the primary outcome and secondary outcomes.

    Time frame: 12 months

  13. Effect size

    Confirmation of the extent of the effect between 6 and 12 months on the primary outcome and secondary outcomes.

    Time frame: 6 and 12 months

  14. Sub group analysis

    Sub group analysis on the primary outcome measure (stratification on primo spa therapy, lymphoedema severity and lymphoedema localization)

    Time frame: 6 months

07

Study locations

13 sites
08

References and documents

Publications

  • Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147-54. doi: 10.1196/annals.1413.014. PubMed 18519968 ↗
  • International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003 Jun;36(2):84-91. PubMed 12926833 ↗
  • Carpentier PH, Blaise S, Satger B, Genty C, Rolland C, Roques C, Bosson JL. A multicenter randomized controlled trial evaluating balneotherapy in patients with advanced chronic venous insufficiency. J Vasc Surg. 2014 Feb;59(2):447-454.e1. doi: 10.1016/j.jvs.2013.08.002. Epub 2013 Oct 15. PubMed 24135621 ↗
  • Pusic AL, Cemal Y, Albornoz C, Klassen A, Cano S, Sulimanoff I, Hernandez M, Massey M, Cordeiro P, Morrow M, Mehrara B. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013 Mar;7(1):83-92. doi: 10.1007/s11764-012-0247-5. Epub 2012 Dec 5. PubMed 23212603 ↗
  • Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2004 Oct;4(5):581-5. doi: 10.1586/14737167.4.5.581. PubMed 19807551 ↗
  • Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003 May;41(5):582-92. doi: 10.1097/01.MLR.0000062554.74615.4C. PubMed 12719681 ↗
  • Devoogdt N, Lemkens H, Geraerts I, Van Nuland I, Flour M, Coremans T, Christiaens MR, Van Kampen M. A new device to measure upper limb circumferences: validity and reliability. Int Angiol. 2010 Oct;29(5):401-7. PubMed 20924341 ↗
  • Lymphœdema Framework. Best Practice for the Management of Lymphœdema. International consensus. London: MEP Ltd, 2006:1-54.
  • Vignes S. [Management of limb lymphedema]. Rev Med Interne. 2012 May;33(5):268-72. doi: 10.1016/j.revmed.2011.12.012. Epub 2012 Jan 31. French. PubMed 22296831 ↗
  • Carpentier PH, Fabry R. Crénothérapie des maladies vasculaires. In: Queneau P, editor. Médecine Thermale, faits et preuves. Paris: Masson Ed; 2000. p. 102-15.
  • Carpentier PH, Colomb M, Poensin D, Satger B. [Incidence of erysipelas of the lower limbs in a spa resort. Efficacy of a strategy of sanitation education (La Lechere: 1992-1997)]. J Mal Vasc. 2001 Apr;26(2):97-9. French. PubMed 11319415 ↗
  • Blaise S, Villemur B, Richaud C, Rastel D, Bucci B, Evra V, Bouchet JY, Satger B; Reseau GRANTED. [Designing a therapeutic education program for patients with lymphedema: live with lymphedema]. J Mal Vasc. 2012 Feb;37(1):1-8. doi: 10.1016/j.jmv.2011.10.006. Epub 2011 Dec 21. French. PubMed 22196687 ↗
  • Carpentier PH, Satger B, Poensin D, Trens C, Arnold M, Trolliet C, Noilhetas J, Chauvin E, Laurès J Therapeutic education combined with balneotherapy in lymphedema patients. Communication acceptée à l'American Venous Forum (Orlando 25/02/2016, publication en préparation)
  • Launois R, Alliot F. Quality of Life Scale in Upper Limb Lymphoedema - A validation Study. Lymphology 33, 2000 (Suppl) : 266-74.
  • Lim P, Li H, Neoh D, Ng SK. Health-related Quality of Life Measurement Tools for Lymphedema: A Review of the Literature. Plast Reconstr Surg Glob Open. 2022 Apr 27;10(4):e4276. doi: 10.1097/GOX.0000000000004276. eCollection 2022 Apr. PubMed 37073384 ↗
  • Keeley, Vaughan; Crooks, Sue; Locke, Jane; Veigas, Debbie; Riches, Katie and Hilliam, Rachel (2010). A quality of life measure for limb lymphoedema (LYMQOL). Journal of Lymphoedema, 5(1) pp. 26-37
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Oct 2025, 75 months.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's 75 months is above that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Dec 2024 → Oct 2025 and completion Dec 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jul 9, 2018
StartActual
Jun 20, 2019
Primary completionActual
Oct 3, 2025was Dec 2024
CompletionActual
Oct 29, 2026was Dec 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Primary completion
Dec 2024→Oct 3, 2025 (actual)
Nov 6, 2026
Study completion
Dec 2025→Oct 29, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Primary completion Dec 2024→Oct 3, 2025 (now actual)
    Study completion Dec 2025→Oct 29, 2026 (now actual)
    + 5 other changes: index terms, verification date, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03580109
Lead sponsor
Association Francaise pour la Recherche Thermale
Collaborators
Floralis
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Jun 20, 2019
Primary completion
Oct 3, 2025
Completion
Oct 29, 2026
Last update
Nov 6, 2026

Study contacts

Patrick CARPENTIER, MD
principal investigator · Hospital University Grenoble

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion